In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) ...

Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in the PI3K pathway, according to results of the randomized ALASCCA study presented at ASCO ...

Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance ...

Aspirin did not provide any clinical benefits in a cohort of patients with colorectal cancer who had no history of cardiovascular disease or stroke.

Among older adults and adults with low ASCVD risk for whom aspirin is not recommended, use of aspirin decreased after 2019 changes in guideline recommendations.

Adjuvant treatment with aspirin is associated with a lower risk of recurrence at 3 years in CRC patients with PI3K pathway ...

For decades, taking low-dose aspirin every day was widely recommended as an easy way to prevent heart attacks and strokes.

After guideline changes, aspirin use dropped off overall, even for higher-risk patients in whom it might still be considered.

The prevalence of daily low-dose aspirin use fell significantly after the American College of Cardiology and the American ...

"The trial shows that aspirin is well tolerated in this patient group but does not demonstrate a significant reduction in ...

Expert Rev Cardiovasc Ther. 2012;10(4):433-439. This article suggests the need to reconsider the benefits of using aspirin in stroke prevention, especially in low-risk patients or patients not ...

A new international clinical trial led by the National Cancer Center Singapore is reporting that three years of aspirin ...